Sartorius Stedim Biotech has entered into an agreement to acquire Novasep’s chromatography process equipment division.
The Novasep chromatography division comprises resin-based batch and intensified chromatography systems, and primarily focuses on high-pressure, multi-use applications for smaller molecules, such as oligonucleotides, peptides and insulin. The division, which employs around 100 people in France, the USA, China and India, is expecting 2020 sales revenue of approximately €37 million.
Since 2018, Novasep and Sartorius have been collaborating on the joint development of an optimised system for a membrane-based, low-pressure chromatography that processes larger molecules more productively.
“I am pleased that we will intensify our successful collaboration with the Novasep team, soon to be under the Sartorius roof,” said Dr René Fáber, head of the Sartorius Bioprocess Solutions division and an executive board member. “The Novasep portfolio will perfectly complement our existing chromatography offering and allow us to provide customers with more options for their manufacturing processes.”
“This deal marks one of the first steps in our Rise-2 strategic program to focus the group towards our core business” said Dr Michel Spagnol, president & CEO of Novasep. “We are delighted to strengthen our relationship with the Sartorius team and believe it will be a great opportunity for the chromatography equipment business to fully deliver its potential and accelerate its growth under this new ownership.“
The acquisition is expected to close during the first half of 2021.
